Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Open Access
- 2 March 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 8, 44
Abstract
Purpose: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic melanoma can be highly effective, but attrition due to progression before TIL administration (32% in prior institutional experience) remains a limitation. We hypothesized that combining ACT with CTLA-4 blockade would decrease attrition and allow more patients to receive TIL. Experimental Design: Thirteen patients with metastatic melanoma were enrolled. Patients received four doses of ipilimumab (3 mg/kg) beginning two weeks prior to tumor resection for TIL generation, then one week after resection, and 2 and 5 weeks after pre-conditioning chemotherapy and TIL infusion followed by IL-2. The primary endpoint was safety and feasibility. Secondary endpoints included of clinical response at 12 weeks and at one year after TIL transfer, disease free survival (DFS) and overall survival (OS). Results: All patients received at least 2 doses of ipilimumab, and 12 of the 13 (92%) received TIL. A median of 6.5x10^10 (2.3x10^10 - 1.0x10^11) TIL were infused. At 12 weeks following infusion there were 5 patients who experienced objective response (38.5%), 4 of whom continued in objective response at one year and one of which became a complete response at 52 months. Median progression-free survival was 7.3 months (95%CI 6.1-29.9 months). Grade ≥3 immune-related adverse events included hypothyroidism (3), hepatitis (2), uveitis (1) and colitis (1). Conclusions: Ipilimumab plus ACT for metastatic melanoma is feasible, well tolerated, and associated with a low rate of attrition due to progression during cell expansion. This combination approach serves as a model for future efforts to improve the efficacy of ACT.Keywords
This publication has 20 references indexed in Scilit:
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2017
- Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic MelanomaJournal of Clinical Oncology, 2016
- Adoptive cell transfer as personalized immunotherapy for human cancerScience, 2015
- Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior ImmunotherapiesClinical Cancer Research, 2013
- Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma PatientsClinical Cancer Research, 2012
- Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic MelanomaJournal of Immunotherapy, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.2002
- Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2Annals of Surgery, 1998
- Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2JNCI: Journal of the National Cancer Institute, 1994